Sigyn Therapeutics (OTCMKTS:SIGY – Get Rating) is one of 223 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Sigyn Therapeutics to related companies based on the strength of its institutional ownership, dividends, risk, earnings, analyst recommendations, profitability and valuation.
Risk & Volatility
Sigyn Therapeutics has a beta of -1.05, suggesting that its share price is 205% less volatile than the S&P 500. Comparatively, Sigyn Therapeutics’ peers have a beta of 1.37, suggesting that their average share price is 37% more volatile than the S&P 500.
Institutional and Insider Ownership
46.7% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 78.5% of Sigyn Therapeutics shares are owned by company insiders. Comparatively, 14.5% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sigyn Therapeutics||N/A||-$3.01 million||-2.44|
|Sigyn Therapeutics Competitors||$1.10 billion||$81.57 million||10.74|
Sigyn Therapeutics’ peers have higher revenue and earnings than Sigyn Therapeutics. Sigyn Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current recommendations and price targets for Sigyn Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sigyn Therapeutics Competitors||883||3396||7584||172||2.59|
As a group, “Surgical & medical instruments” companies have a potential upside of 21.13%. Given Sigyn Therapeutics’ peers higher possible upside, analysts clearly believe Sigyn Therapeutics has less favorable growth aspects than its peers.
This table compares Sigyn Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sigyn Therapeutics Competitors||-1,355.92%||-145.04%||-26.44%|
Sigyn Therapeutics peers beat Sigyn Therapeutics on 7 of the 10 factors compared.
Sigyn Therapeutics Company Profile
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.